logo

For the Inventor, By the Inventor

St. Louis Park, MN, United States of America

R Scott McIvor

This inventor holds 10 USPTO granted patents and 24 published patent applications and 2 EPO patents. Top assignees: Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: R Scott McIvor. Retrieved from https://idiyas.com/inventor/r-scott-mcivor

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 90.0

 

Average Co-Inventor Count = 4.4

ph-index = 6

Forward Citations = 145(Granted Patents)


Company Filing History:

goldMedal8 out of 2,372 
 
Regents of the University of Minnesota
 patents
silverMedal3 out of 15 
 
Intima Bioscience, Inc.
 patents
bronzeMedal3 out of 3,696 
 
The United States of America, as Represented by the Secretary, Department of Health and Human Services
 patents
4. 2 out of 11 
 
Healthpartners Research & Education
 patents
5. 2 out of 15 
 
Regenxbio Inc.
 patents
6. 1 out of 4 
 
Immusoft Corporation
 patents
7. 1 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 12121567 - Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase (2024-10-22),
2. 11583556 - Modified cells and methods of therapy (2023-02-21),
3. 11147837 - Modified cells and methods of therapy (2021-10-19),
4. 11103582 - Method to achieve extended expression of DNA infused into liver (2021-08-31),
5. 10166255 - Intracellular genomic transplant and methods of therapy (2019-01-01),
6. 9827295 - Methods to treat mucopolysaccharide type I or deficiency in alpha-L-iduronidase using a recombinant adeno-associated virus encoding alpha-L-iduronidase (2017-11-28),
7. 9249424 - Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases (2016-02-02),
8. 8609088 - Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases (2013-12-17),
9. 7592321 - Methods of treating lysosomal storage related diseases by gene therapy (2009-09-22),
10. 6485722 - Method for selective engraftment of drug-resistant hematopoietic stem cells (2002-11-26),

Title: R Scott McIvor: Innovator in Gene Therapy and Cancer Treatment

Introduction

R Scott McIvor is a prominent inventor based in St. Louis Park, MN, known for his significant contributions to the fields of gene therapy and cancer treatment. With a total of 10 patents to his name, McIvor has made remarkable strides in developing innovative methods to address complex medical conditions.

Latest Patents

Among his latest patents, McIvor has developed methods to treat mucopolysaccharidosis type II, utilizing a recombinant adeno-associated virus (AAV) vector that encodes iduronate-2-sulfatase. He has also created a method to prevent, inhibit, or treat symptoms associated with diseases of the central nervous system by administering a rAAV encoding a gene product associated with the disease. Additionally, McIvor has disclosed genetically modified compositions, including non-viral vectors and T cells, for treating cancer, along with methods for making and using these compositions.

Career Highlights

Throughout his career, McIvor has worked with esteemed institutions such as the University of Minnesota and Intima Bioscience, Inc. His work has been pivotal in advancing therapeutic techniques that leverage genetic modifications to combat serious health issues.

Collaborations

McIvor has collaborated with notable colleagues, including Branden Moriarity and Beau R Webber, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

R Scott McIvor's work exemplifies the intersection of innovation and healthcare, showcasing his dedication to improving treatment options for patients through groundbreaking research and development. His contributions continue to influence the fields of gene therapy and cancer treatment significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…